CA2906356A1 - Antibodies to mica and micb proteins - Google Patents

Antibodies to mica and micb proteins Download PDF

Info

Publication number
CA2906356A1
CA2906356A1 CA2906356A CA2906356A CA2906356A1 CA 2906356 A1 CA2906356 A1 CA 2906356A1 CA 2906356 A CA2906356 A CA 2906356A CA 2906356 A CA2906356 A CA 2906356A CA 2906356 A1 CA2906356 A1 CA 2906356A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
antibody
mica
micb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2906356A
Other languages
English (en)
French (fr)
Inventor
Ian Wayne Cheney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novelogics Biotechnology Inc
Original Assignee
Novelogics Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novelogics Biotechnology Inc filed Critical Novelogics Biotechnology Inc
Publication of CA2906356A1 publication Critical patent/CA2906356A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2906356A 2013-03-15 2014-03-15 Antibodies to mica and micb proteins Abandoned CA2906356A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361801329P 2013-03-15 2013-03-15
US61/801,329 2013-03-15
US201461940372P 2014-02-15 2014-02-15
US61/940,372 2014-02-15
PCT/IB2014/001157 WO2014140904A2 (en) 2013-03-15 2014-03-15 Antibodies to mica and micb proteins

Publications (1)

Publication Number Publication Date
CA2906356A1 true CA2906356A1 (en) 2014-09-18

Family

ID=51538216

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2906356A Abandoned CA2906356A1 (en) 2013-03-15 2014-03-15 Antibodies to mica and micb proteins

Country Status (6)

Country Link
US (2) US10851148B2 (enExample)
EP (1) EP2970490A4 (enExample)
JP (2) JP6518199B6 (enExample)
AU (1) AU2014229476B2 (enExample)
CA (1) CA2906356A1 (enExample)
WO (1) WO2014140904A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8475785B2 (en) 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
WO2015179627A1 (en) * 2014-05-21 2015-11-26 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti bip or anti mica antibodies
US10174095B2 (en) 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
KR20170109582A (ko) 2015-02-06 2017-09-29 히트 바이오로직스, 인코퍼레이티드 벡터 공동 발현 백신 및 공동 자극 분자
NZ742663A (en) * 2015-12-04 2023-02-24 Dana Farber Cancer Inst Inc Vaccination with mica/b alpha 3 domain for the treatment of cancer
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
EP3529280A4 (en) * 2016-10-19 2020-04-22 Novelogics Biotechnology, Inc. ANTIBODIES AGAINST MICA AND MICB PROTEINS
CN107964041B (zh) * 2016-10-20 2023-08-01 中国科学院广州生物医药与健康研究院 高稳定性和高亲和力的dmic及其制法
JP2019535250A (ja) * 2016-10-29 2019-12-12 ジェネンテック， インコーポレイテッド 抗ｍｉｃ抗体及び使用方法
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
US20200023071A1 (en) 2017-02-06 2020-01-23 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
CN112566659A (zh) * 2018-01-25 2021-03-26 库利南Mica公司 Mica/b抗体和使用方法
BR112020018539A2 (pt) 2018-03-23 2020-12-29 Bristol-Myers Squibb Company Anticorpos contra mica e/ou micb e usos dos mesmos
JP7438988B2 (ja) 2018-06-13 2024-02-27 ノバルティス アーゲー Ｂｃｍａキメラ抗原受容体及びその使用
JP7370376B2 (ja) * 2018-07-31 2023-10-27 クリナン ミカ コーポレイション Ｍｉｃａ／ｂシェディングをブロックする抗ｍｉｃａ／ｂ抗体および使用方法
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
MX2021007271A (es) 2018-12-21 2021-07-15 Onxeo Nuevas moleculas de acido nucleico conjugado y sus usos.
WO2020214957A1 (en) * 2019-04-19 2020-10-22 Tcrcure Biopharma Corp. Anti-pd-1 antibodies and uses thereof
AU2020336023A1 (en) * 2019-08-23 2022-03-03 Northwestern University Materials and methods for activating antigen-specific T cell responses
TW202214857A (zh) 2020-06-19 2022-04-16 法商昂席歐公司 新型結合核酸分子及其用途
JP7821779B2 (ja) * 2020-08-10 2026-02-27 イナート・ファルマ・ソシエテ・アノニム 抗体を使用した細胞表面ｍｉｃａ及びｍｉｃｂの検出
CN112574311B (zh) * 2020-12-14 2022-03-25 广州康盛生物科技股份有限公司 双mic结合活性的抗体及其应用
US20240216554A1 (en) * 2021-05-04 2024-07-04 Actinium Pharmaceuticals, Inc. Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer
US20240294926A1 (en) 2021-12-16 2024-09-05 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
WO2023196598A2 (en) * 2022-04-08 2023-10-12 D2M Biotherapeutics Limited Anti-mica/b antibodies and uses thereof
KR102783449B1 (ko) * 2022-06-15 2025-03-19 주식회사 셀리드 자연 살해 ｔ 세포의 리간드와 암 항원을 적재한 자연 살해 세포를 포함하는 백신

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2275141A1 (en) 1996-10-29 1998-05-07 Thomas Spies Cell stress regulated human mhc class i gene
US20050265996A1 (en) 2004-04-30 2005-12-01 Biopheresis Technologies, Inc. Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients
WO2003029436A2 (en) 2001-10-04 2003-04-10 Immunex Corporation Ul16 binding protein 4
EP1578923A4 (en) * 2002-04-22 2009-01-21 Hutchinson Fred Cancer Res SOLUBLE MIC POLYPEPTIDE AS A MARKER FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER AND AUTOIMMUNE DISEASES OR DISEASES
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
DE102004042894A1 (de) 2004-08-30 2006-03-02 Eberhard-Karls-Universität Tübingen Verwendung von Blockern der NKG2D-Rezeptor-/NKG2D-Liganden-Interaktion bei Autoimmunerkrankungen
EP2083857A4 (en) 2006-09-22 2010-03-24 Dana Farber Cancer Res Inc METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
EP3187507A1 (en) 2007-04-23 2017-07-05 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by erp5
US8182809B1 (en) 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
US10865233B2 (en) 2008-12-18 2020-12-15 Dana-Farber Cancer Institute, Inc. NKG2D-fc for immunotherapy
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
TWI408370B (zh) 2011-05-19 2013-09-11 長庚大學 胰臟癌之血清生物檢測標誌及其應用
US8753640B2 (en) * 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
EP2760471B9 (en) 2011-09-30 2017-07-19 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
CA2862101A1 (en) 2012-02-07 2013-08-15 Innate Pharma Mica binding agents
EP2626994B1 (en) 2012-02-08 2019-04-03 GE Oil & Gas UK Limited Supplying electrical power to subsea equipment
US20160030659A1 (en) 2013-03-15 2016-02-04 Novelogics Biotechnology, Inc. Methods and devices for removal of immunosuppressive ligands

Also Published As

Publication number Publication date
JP2019194180A (ja) 2019-11-07
EP2970490A2 (en) 2016-01-20
EP2970490A4 (en) 2017-04-26
WO2014140904A3 (en) 2014-12-31
AU2014229476A1 (en) 2015-10-01
US10851148B2 (en) 2020-12-01
JP6518199B2 (ja) 2019-05-22
US20210040173A1 (en) 2021-02-11
JP6518199B6 (ja) 2019-06-12
US20160046689A1 (en) 2016-02-18
WO2014140904A2 (en) 2014-09-18
JP2016512223A (ja) 2016-04-25
AU2014229476B2 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
US20210040173A1 (en) Antibodies to mica and micb proteins
US11066471B2 (en) Antibodies to MICA and MICB proteins
TWI828673B (zh) Vista抗原結合分子
US10675357B2 (en) Antibodies having specificity to nectin-4 and uses thereof
US20250289880A1 (en) Use of anti-fam19a5 antibodies for treating cancers
TWI772275B (zh) 特異性結合pd-1、tim-3或pd-1與tim-3之抗體及其用途
ES2984950T3 (es) Anticuerpos específicos para CD3 y sus usos
KR20210015902A (ko) Psma 결합제 및 이의 용도
JP7716623B2 (ja) 排出ポンプ－癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
US20260028405A1 (en) Anti-cd16a antibodies and methods of use thereof
KR20230008751A (ko) 피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
NZ751584B2 (en) Antibodies to mica and micb proteins
NZ751584A (en) Antibodies to mica and micb proteins
RU2780537C2 (ru) Cd3-специфические антитела и их применение
HK40046552B (zh) 对cd3特异性的抗体及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190313

FZDE Discontinued

Effective date: 20220712

FZDE Discontinued

Effective date: 20220712